Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a leading biopharmaceutical company, has announced that it has received tacit approval from the US Food and Drug Administration (FDA) to commence a clinical study for its drug candidate, GenSci122, in patients with advanced solid tumors.
GenSci122 is a small molecule inhibitor of KIF18A, a member of the Kinesin-8 family, which includes KIF18A, KIF18B, and KIF19A. This family plays a crucial role in cell mitosis, ensuring the correct arrangement of polar chromosomes and appropriate spindle tension. Tumor cells with chromosomal instability (CIN) often exhibit high expression of KIF18A compared to normal diploid cells. Targeting KIF18A could, therefore, present a therapeutic strategy for treating tumors, with the added benefit that inhibiting KIF18A does not significantly impact the proliferation of normal diploid cells.
The clinical study for GenSci122 represents a significant step forward in the development of targeted therapies for cancer, potentially offering a new treatment option for patients with advanced solid tumors. The FDA’s tacit approval allows Changchun High & New Technology Industries to move forward with exploring the efficacy and safety of GenSci122 in a clinical setting.- Flcube.com
